X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - Clinical Trials News - 15/Aug 00:08

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced positive...

Articles similaires

Sorry! Image not available at this time

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

drugs.com - 03/Sep 01:09

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

drugs.com - 05/Sep 05:09

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

drugs.com - 05/Sep 05:09

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes

financialpost.com - 09/Sep 16:02

VANCOUVER, British Columbia & NEW YORK — Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for...

Sorry! Image not available at this time

Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes

financialpost.com - 09/Sep 16:02

VANCOUVER, British Columbia & NEW YORK — Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for...

Sorry! Image not available at this time

MindBio advances world-first psychedelic microdosing clinical trials

themarketherald.ca - 29/Aug 14:44

MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.

Sorry! Image not available at this time

Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome

pharmabiz.com - 04/Sep 00:00

Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...

Sorry! Image not available at this time

Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome

pharmabiz.com - 04/Sep 00:00

Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...

Les derniers communiqués